A novel pyranoside mimetic compound, 5, 6, 7, 8, [1, 3] oxazine), was designed and synthesized.
Introduction
Synthetic heterocyclic compounds have been used extensively for drug development and the treatment of diseases including cancer (1) . Among them, oxazines are well known for their potential biological effects, for example, the inactivation of chymotrypsin by 5-butyl-3H-l,3-oxazine-2,6-dione (2) . In addition, 5-β-D-ribofuranosyl-l,3-oxazin-2,4-dione, a Cribonucleoside antibiotic (minimycin), is used as an anti-tumor agent (3) and 5-methyl-3H-1,3-oxazine-2,6-dione is used as a suicide inactivator of serine proteases (4) . In the search for an effective therapeutic agent for cancer, which targets multiple pathways, we designed and synthesized a novel six-membered oxazine compound, DMBO (2-(2,6-difluorophenyl)-4a,5,6,7,8,8a-hexahydro-4a-(4-methoxyphenyl)-4H-benzo[e] [1, 3] oxazine), a class of sugar mimetic, in which the ring carbon has been replaced by a nitrogen atom. DMBO is considered to mimic the pyranoside structure of sugar residues in heparan sulfate (HS).
HS on cell surfaces modulates signal transduction to tumor cells by interacting with
various growth factors such as fibroblast growth factor-2 (FGF-2) (5), vascular epidermal growth factor (VEGF) (6), and heparin-binding epidermal growth factor-like growth factor (HB-EGF) (7) . Cell surface and extracellular matrix HS plays a major role in tumor metastasis, and acts as a storage shed for various proteins (8) . Heparanase, an endo-β-Dglucuronidase family member, promotes tumor cell invasion by degrading HS in the extracellular matrix (ECM) (9, 10) . Heparanase promotes cell proliferation, metastasis and angiogenesis by releasing growth factors such as FGF-2 and VEGF from HS (11, 12) . Several studies have shown that HS mimetics act as antitumor agents. For example, anti-tumor and anti-heparanase activities of a non-sugar-based HS mimetic compound KI-105 have been reported (13) .
In addition to the matrix components and matrix-degrading enzymes, malignant cells produce a variety of soluble factors such as tumor necrosis factor-α (TNF-α), VEGF, and 4 HB-EGF, which play a major role in tumor progression. Heparin-binding growth factors like FGF-2, VEGF and HB-EGF have been implicated in the metastatic process (14) . Increasing evidence shows that TNF-α acts as a key mediator for local inflammation and also in the development of cancer, suggesting that anti-TNF-α therapy might be effective against pancreatic tumor growth and metastasis (15) . VEGF plays a major role in both vasculogenesis and angiogenesis by triggering a tyrosine kinase pathway (16) . Some members of the VEGF family stimulate cellular responses by binding to cell-surface HS-PGs as co-receptors (17) . Therefore, effective VEGF antagonists or the VEGF receptor agonists that mimic HS may be good tools to inhibit VEGF production. HB-EGF activates at least three signal transduction pathways, which are involved in proliferation, the secretion of VEGF, and the stimulation of chemotaxis in cancer cells (18) . The expression of ligands for the EGF receptor (EGFR), such as transforming growth factor-α, is also often increased in gliomas, resulting in an autocrine loop that contributes to the growth autonomy of glioma cells (19) . Importantly, HB-EGF and EGF act downstream by binding to EGFR on the cell surface with high affinity (20) . Therefore, it is reasonable to expect either inhibition of the expression of HB-EGF or blocking of the EGFR pathway to have therapeutic value in the treatment of a variety of cancers. This notion is consistent with the finding that a neutralizing antibody against HB-EGF blocked the transactivation of EGFR and inhibited cell proliferation (21) . DMBO mimics HS structurally. Here, we demonstrate DMBO's ability to bind various growth factors/cytokines such as TNF-α, VEGF and HB-EGF, anti-inflammatory activity, and anti-metastatic activity in vivo.
Materials and Methods
Chemicals. Cisplatin, suramin, recombinant human HB-EGF (rh-HB-EGF), rhmidkine, rh-TNF-α, rh-FGF-2, rh-VEGF 165 , and rh-pleotrophin were purchased from Wako Pure Chemicals Co. (Osaka, Japan). Mifepristone and lipopolysaccharide (LPS) were from Sigma (St. Louis, MO). 100X non-essential amino acids, β-mercaptoethanol, 100X sodium pyruvate and L-glutamine were from GIBCO (Auckland, New Zealand). The cell proliferation assay kit Tetracolor One was obtained from Seikagaku Corp. (Tokyo, Japan) and the Diff-Quick solution was from International Reagent Corp. (Kobe, Japan). All other chemicals and reagents used were of the highest commercial grade available. The synthesis, characterization and the crystal structure of DMBO used in this study are described in the Supplementary Information.
Animals and cell lines. Nine-week-old female C3H/HeN mice and 10-week-old male C57BL/6 mice were obtained from Japan SLC (Hamamatsu, Japan) and kept in standard housing. All the experiments were performed according to a protocol approved by the local animal care committee of Hokkaido University. LM8G7, a highly metastatic murine osteosarcoma cell line with the potential to invade the liver, was cloned from LM8G5 cells (22) as described (23) and cultured in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS) (Thermo Trace, Melbourne, Australia), streptomycin (100 μg/ml), penicillin (100 units/ml), 100X non-essential amino acids, β-mercaptoethanol (50 μM), 100X sodium pyruvate, and L-glutamine (2 mM) at 37 °C in a humidified 5% CO 2 atmosphere. The cells were harvested after incubation with 0.1% trypsin/1 mM EDTA in PBS for 5 min at 37 °C followed by gentle flushing with a pipette, and subcultured thrice a week. Human ovarian cancer cells (OVSAHO and SKOV-3) and mouse vascular endothelial cells (UV♀2) were purchased from RIKEN Cell Bank, Japan.
The OVSAHO cells were cultured in RPMI medium supplemented with 10% (v/v) FBS, L-glutamine (2 mM), and NaHCO 3 (10%). The SKOV-3 cells were cultured in McCoy's 5A medium supplemented with 10% (v/v) FBS and L-glutamine (2 mM). The UV♀2 cells were maintained in DMEM supplemented with 10% (v/v) FBS.
Surface plasmon resonance (SPR) assay. To introduce DMBO onto a gold surface for SPR measurements, photoaffinity-linker-coated gold substrates (PGSs) were prepared according to our previous report (24) . The detailed materials and methods for the SPR assay are provided in Supplementary Information. The interaction between DMBO and the growth factors/cytokines such as TNF-α, HB-EGF, and VEGF were carried out using SPR imaging instrument (TOYOBO, Osaka, Japan). The SPR image and signal data were collected with an SPR analysis program (TOYOBO). The SPR difference image was constructed by using the Scion Image program (Scion, MD).
TNF-α binding assay. The binding of TNF-α to its antibody was measured using a colorimetric-based Quantikine ELISA kit (R&D systems). The effects of DMBO on the binding were determined by incubating different concentrations of DMBO (15 to 148 μM) with the recombinant mouse TNF-α for 30 min at room temperature, transferring 100 μL of the reaction mixture to a 96-well plate coated with a polyclonal antibody specific for mouse TNF-α, incubating for 2 h at room temperature. After washing, 100 μL of horseradish peroxidase (HRP)-conjugated anti-TNF-α antibody was added to each well. The mixture was incubated for another 2 h, aspirated, washed and mixed with 100 μL of the substrate solution (a mixture of H 2 O 2 and tetramethyl benzidine). After 30 min at room temperature, 100 μL of a stop solution (dil. HCl) was added and the optical density was determined using a model 680 micro plate reader (Bio-Rad) at 450 nm. Heparin (50 μg/ml) from porcine intestinal mucosa was used as a positive control.
Anti-inflammatory assay. C57BL/6 mice (20-25g) were injected intraperitoneally with 2 ml of 3% thioglycolate (TG) broth (Sigma-Aldrich) or sterile-saline as described earlier (25). After 10 min, DMBO (0.5, 1.5 or 5 mg/kg) suspended in saline was injected through a lateral tail vein. After 24 h, LPS (1.0 μg) was injected intraperitoneally, and 1 h later, the peritoneal cavities were lavaged with 4 ml of PBS containing 3 mM EDTA. After the total number of inflammatory cells was counted, the lavage fluid (2 ml) was centrifuged at 1,500 rpm for 5 min, and the supernatant was stored at -20 °C for the detection of TNF-α.
The amount of TNF-α was determined by using a Quantikine ELISA kit. Heparin (10 mg/kg) was used as a positive control. Wound healing assay. LM8G7 cells were seeded in a 6-well plate and allowed to grow to complete confluence. Subsequently, a plastic pipette tip was used to scratch the cell monolayer to create a cleared area, and the wounded LM8G7 cell layer was washed with a fresh medium to remove loose cells, and photographed using CKX41 Olympus microscope (Olympus, Tokyo, Japan) equipped with x10 objective lenses. The cells were incubated with or without DMBO (0.2 μM), and the inhibition of the wound healing by DMBO was measured after 24 h incubation. The percentage of the distance of the DMBO-treated area compared with that of the control wound area was calculated.
Cell adhesion assay. Tumor cell adhesion to immobilized P-selectin or fibronectin was quantitated as described previously (26, 27) . Briefly, a 96-well microtiter plate (Maxisorp; Nunc, Roskilde, Denmark) was coated with P-selectin (5 μg/ml in PBS) or fibronectin (5 μg/ml in 0.1 M NaHCO 3 ) at 4 °C overnight. The plate was washed three times 8 with PBS, blocked with 3% bovine serum albumin (BSA) in PBS for 2 h at room temperature, and washed again. The plate was incubated with DMBO (27 or In vitro angiogenesis assay. In vitro angiogenesis assay was performed according to the previously reported procedure (30) . Details are provided in Supplementary Information.
Heparanse activity assay.
A heparan-degrading assay kit (Takara Biomedical, Otsu, Japan) was used according to the manufacturer's directions. Briefly, 50 μL of biotinylated HS was incubated with 31 mIU of recombinant human heparanase in the presence or absence of serially diluted DMBO (59 to 236 μM). After 45 min at 37 °C, the reaction mixture was transferred to a microplate, where a fusion protein comprising the cell binding domain of human fibronectin and human FGF-2 was immobilized, and incubated at 37 °C for 15 min.
The wells were washed, 100 μL of an avidin-peroxidase (POD) conjugate and 100 μL of POD substrate were added, and the mixture was incubated for 30 min. The reaction was stopped by adding 100 μL of a stop solution and the absorbance was measured at 450 nm.
Suramin (70 μM) was used as a positive control (31) .
In vitro heparan-degrading assay. LM8G7 (1 x 10 6 ) cells were seeded into a 6-well plate and incubated overnight. After 24 h, the cells were incubated with DMBO at concentrations of 55, 104, and 206 μM in triplicate. To determine the effect of DMBO on the heparan-degrading activity of LM8G7, the cells were further incubated for 48 h at 37 °C. The cells were collected by centrifugation, and a whole-cell lysate was prepared as reported (32) .
Protein concentrations of the samples were determined using a BCA (bicinchoninic acid) assay kit (Thermo Fisher Scientific Inc., IL), and adjusted to 0.1 mg/ml. The heparandegrading activity in DMBO-treated/untreated cell lysates was measured. Kit (R&D systems). Briefly, with known amounts of recombinant VEGF as standards, the control or DMBO-treated cell lysates were added to a 96-well plate, which was pre-coated with the polyclonal antibody specific to mouse VEGF, and incubated for 2 h. Bound VEGF was detected by adding an HRP-conjugated polyclonal antibody against mouse VEGF. After 2 h, 100 μL of the substrate chromogen was added and allowed to react for 30 min with the POD-conjugate. The reaction was stopped and the VEGF content was quantified in a microplate reader at 450 nm.
Statistical analysis. The statistical analysis was done using a software Origin 8 (OriginLab). The Mann-Whitney U test was used to determine P-values.
Results
Synthesis of DMBO. The DMBO was prepared by the cyclization of 1-[2-amino-1-(4-methoxy-phenyl)-ethyl]-cyclohexanol monoacetate with 2,6-difluoro benzaldehyde in the presence of potassium carbonate ( Supplementary Fig. S1A ). Further, we obtained DMBO in single crystalline form (Supplementary Fig. S1B ). The comparison of the pyranose ring of the HS disaccharide unit and its mimetic oxazine ring of DMBO is also provided ( Supplementary   Fig. S1C ). (Fig. 3A) . In contrast, mice treated intravenously with DMBO at 0.5, 1.0 or 1.5 mg/kg were completely free of metastatic nodules in the liver (Fig. 3B) . Measurements of liver weight, which reflects tumor burden, gave similar results, with DMBO almost completely suppressing the increase in liver weight by inhibiting the formation of tumor nodules. The animals tolerated the dosages of DMBO well, showing no signs of toxicity or weight loss during the experiments. Heparin (5 mg/kg), a positive control, also prevented the increase in liver weight (Fig. 3C ) by suppressing the formation of metastatic nodules in the liver.
Examination

Effects of DMBO on the migration, adhesion and invasion of LM8G7 cells.
Effects of DMBO on the migration, adhesion and invasion of highly metastatic LM8G7 cells were studied. The wound healing assay was performed to examine its effects on migration.
DMBO (0.2 μM) completely inhibited the migration of LM8G7 cells after a scratch was made (Fig. 4A) . The distance between the edges of the wound was measured at 0 h and normalized to 100% (Fig. 4B) . We next examined the effect of DMBO (27 or 54 μM) on the adhesion of LM8G7 cells to P-selectin or fibronectin. DMBO inhibited the adhesion LM8G7 cells to P-selectin by 36 and 48% (Fig. 4C ) as compared to control, which is relatively weaker when compared to the inhibition of the adhesion to fibronectin by 48 and 72% at 27
and 54 μM, respectively. Further, DMBO inhibited the invasion of LM8G7 cells into Matrigel TM at 0.2 and 0.5 μM by 74 and 75%, respectively, as compared to the control (Fig.   4D ).
Effects of DMBO on the viability and proliferation of normal and cancer cells.
Given the importance of DMBO as an anti-inflammatory and anti-metastatic agent, its effects on the proliferation of various tumor cells were examined. First, however, the cytotoxicity of DMBO was tested using mouse endothelial cells (UV♀2). DMBO had no significant effect on the proliferation of UV♀2 cells (13% inhibition at 195 μM), whereas mifepristone (33) strongly inhibited proliferation (87% at 155 μM) (Fig. 5A) . However, DMBO inhibited the proliferation of HB-EGF-positive SKOV-3 cells dose-dependently. DMBO at 195 μM completely inhibited the proliferation of SKOV-3 cells (99%), whereas mifepristone at 155 μM had a lesser effect (63%) (Fig. 5B) . Further, the effects of DMBO (24 to 197 μM) on the proliferation of OVSAHO and mouse osteosarcoma LM8G7 cells were monitored using the RT-CES system. DMBO inhibited the proliferation of highly metastatic TNF-α-expressing OVSAHO and VEGF-expressing LM8G7 cells dose-dependently (Fig. 5C & D) with an IC 50 value of 6 and 13 μM, respectively. Therefore, the above results indicated that DMBO specifically and markedly inhibits the growth of cancer cells with little cytotoxic effect on normal cells.
DMBO inhibits angiogenesis in vitro.
Anti-angiogenic effects of DMBO were also examined using an in vitro model. DMBO selectively inhibited the formation of vascular 14 tubes on ECMatrix TM in a dose-dependent manner (Supplementary Fig. S6 ). The inhibition was 52 and 82% at 200 and 500 nM, respectively.
Effects of DMBO on the catalytic activity of heparanase. The expression of
heparanase by tumor cells is closely related to its metastatic potential (34) . To investigate the effects of DMBO on the catalytic activity of heparanase, biotinylated HS was incubated at 37
°C with recombinant human heparanase in the presence or absence of DMBO (59 to 236 μM). Strong inhibition was observed at 236 μM DMBO (Fig. 6A ) and the inhibition was dose-dependent from 118 to 236 μM. However, the effect was less significant at 59 μM. An inhibitor for heparanase, suramin, prevented the catalytic activity of human heparanase at 70 μM (Fig. 6A) . (Fig. 6B ). DMBO at 104 and 206 μM significantly inhibited the degradation of intact HS by 63 and 85%, respectively, but DMBO at 55 μM failed to inhibit the heparandegrading activity (Fig. 6B) . Thus, DMBO at higher concentrations significantly abolished the heparan-degrading activity of LM8G7 cells.
Inhibition of heparan-degrading
Effects of DMBO on the secretion of VEGF by LM8G7 cells. SPR analysis
demonstrated that DMBO directly bound to VEGF (Fig. 1D) . Hence, effects of DMBO on the secretion of VEGF by LM8G7 cells were studied. A significant amount of VEGF (0.42 ± 0.05 ng/ml) was detected in the control culture medium of LM8G7 cells, whereas exposure of the cells to DMBO inhibited the secretion of VEGF in a dose-dependent manner (Fig. 6C ).
DMBO at 74, 148, and 295 μM effectively inhibited the secretion of VEGF by 18, 37, and 40%, respectively.
Discussion
The metastasis of cancer cells to specific sites in the body is mediated through a complex molecular process that involves multiple cell surface receptors, basement membrane components, intercellular adhesion molecules, and cytokines/growth factors (36) . Once the molecules and their ligands involved in the pathways of cancer progression have been identified, it should be possible to develop synthetic compounds that inhibit these processes.
Heparin and most of the HS mimetics that act to enhance the inhibition of inflammation and tumor metastasis are sulfated oligosaccharides (e.g., heparin derivatives, laminarin sulfate, and chitin derivatives) (37) (38) (39) . It is difficult to develop and synthesize HS mimetic compounds, which perform multiple biological functions in vivo and in vitro. Low molecular weight HS mimetics with high specificity are rare. Among HS mimetics, PI-88 (phospho mannopentaose) has been reported as an antitumor agent, which significantly inhibits tumor growth, metastasis, and angiogenesis (40) . An HS mimicking a pseudodisaccharide has been reported as an inhibitor of heparanase (41) . All these compounds have a sugar-based structure. We herein report the synthesis and biological activities of a novel non-sugar-based compound, DMBO, which can mimic the pyranoside structure of sugar residues in HS.
We demonstrated here that DMBO strongly interacted with TNF-α, VEGF and HB-EGF directly as detected by SPR assay. The SPR signal of DMBO was significantly stronger than that of other structurally similar compounds having the same oxazine nucleus ( Supplementary Fig. S3-S5 ). This indicates that the 2,6-difluorophenyl group of DMBO is important for the interaction with TNF-α, VEGF and HB-EGF. DMBO did not bind to other heparin-binding growth factors such as pleiotrophin and midkine (data not shown).
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The biological activities of TNF-α have attracted much attention, and strategies specifically to HB-EGF, supports this observation. Additional studies will be necessary to clarify the underlying mechanism. A result similar to this observation was reported for the diphtheria toxin (CRM197), which binds to HB-EGF and suppresses the growth of ovarian cancer cells (50) .
Although we have synthesized many oxazine derivatives that bear the same nucleus as that of DMBO, to the best of our knowledge, this is the first report on a synthetic oxazine that mimics HS interacts directly with growth factors/cytokines, and has potential anti-metastatic activity. However, additional studies are needed to elucidate the mechanism of action of DMBO toward cancer cells. mice per group. * P < 0.05 and ** P < 0.01 versus control. *** P < 0.005 versus control. 
